Companies
Align Technology
S&P 500Health Care· USA

ALGN

Status-Quo-Player

Align Technology

$180.67

+4.32%

Open $171.74·Prev $173.20

as of 13 Apr

STATUS-QUO-PLAYER

Power Core

Moat in one sentence: Align Technology's moat is the closed-loop integration of proprietary scanning hardware, AI-driven treatment planning software, and the world's largest orthodontic outcome dataset, creating a workflow dependency that competitors cannot replicate by copying the physical product alone.

Published1 Apr 2026
UniverseS&P 500
SectorHealth Care

Direction of Movement

Stabilized at Scale, Neither Accelerating nor Retreating

ROC 200

-6.5%

Company Profile

Align Technology, Inc. is a global medical device company specializing in the design, manufacture, and marketing of orthodontic and restorative dentistry products. It primarily offers the Invisalign system of clear aligners, including full, teen, and assist products, along with Vivera retainers, to treat malocclusion and straighten teeth for patients worldwide. The company also provides iTero intraoral scanning systems, featuring a single hardware platform with restorative or orthodontic software options, upgrades, leases, pre-owned scanners, subscription software, disposables, and pay-per-scan services. Additionally, Align Technology delivers exocad CAD/CAM software solutions that integrate workflows for dental labs and practices, alongside 3D printing technologies and digital platforms like ClinCheck for treatment planning. Operating through Clear Aligner and Systems and Services segments, it supports dental professionals with training, certification, and tools for digital orthodontics and restorative dentistry, impacting the health technology sector focused on medical specialties. Founded in 1997 and headquartered in Tempe, Arizona, Align Technology plays a key role in advancing invisible orthodontics and intraoral imaging solutions.

Sector

Healthcare

Industry

Medical Instruments & Supplies

Employees

20,290

This page is for informational purposes only and does not constitute investment advice. L17X Research is an independent research service.